Injectable Prostaglandin E1 Multiple Strengths Recalled for Sterility Concerns
Pharmacy Innovations is recalling multiple strengths of injectable Prostaglandin E1 nationwide due to lack of sterility assurance. FDA inspection found insanitary conditions at the manufacturing facility.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an injectable drug recall classified as FDA Class II with a serious hazard (lack of sterility assurance due to insanitary facility conditions). No illnesses or injuries are reported in the source text. The recall scores as High because injectable drugs represent risk-of-harm products where contamination poses significant potential harm; however, without reported hospitalizations or illnesses, it does not meet the threshold for Severe.
Plain-English summary
Pharmacy Innovations is recalling multiple formulations of injectable Prostaglandin E1 distributed nationwide in the United States. The recall was initiated due to lack of assurance of sterility, following an FDA inspection that revealed insanitary conditions at the company's manufacturing facility located at 2936 W 17th St., Erie, PA.
The recalled products include Prostaglandin E1 in multiple strengths ranging from 17 mcg/mL to 60 mcg/mL in various vial sizes (1 mL and 3 mL). These are prescription injectable medications.
Consumers and healthcare providers who have received these products should stop using them and contact Pharmacy Innovations or consult their healthcare provider about appropriate alternatives. Patients currently using these medications should not discontinue use without medical guidance, but should contact their healthcare provider immediately to discuss their options.
The recalled product
- Product
- PROSTAGLANDIN (PE1) 45MCG (1ML VIAL) INJECTABLE PROSTAGLANDIN E1 17MCG/ML (1ML VIAL) INJECTABLE PROSTAGLANDIN E1 20MCG/ML (1ML VIAL) INJECTABLE PROSTAGLANDIN E1 22.5MCG/ML (1ML VIAL) INJECTABLE PROSTAGLANDIN E1 23MCG/ML (1ML VIAL) INJECTABLE PROSTAGLANDIN E1 30MCG/ML (1ML VIAL) I
- Manufacturer
- Pharmacy Innovations
- Category
- Drug — Injectable
- Hazard
- lack-of-sterility
- facility-contamination
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27